Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aker BioMarine ASA's total equity for the quarter that ended in Jun. 2026 was kr1,302 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
The historical data trend for Aker BioMarine ASA's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aker BioMarine ASA (OSL:AKBM) has a Total Equity of kr1,302 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Aker BioMarine ASA and its competitors.
Is Aker BioMarine ASA's Total Equity too high?
Aker BioMarine ASA's current Total Equity is kr1,302 Mil. Overall, Aker BioMarine ASA has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aker BioMarine ASA's Total Equity compare to KHC and GIS?
Aker BioMarine ASA's Total Equity of kr1,302 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Consumer Packaged Goods company?
A good Total Equity depends on the Consumer Packaged Goods industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Aker BioMarine ASA and its competitors. Aker BioMarine ASA's current Total Equity is kr1,302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aker BioMarine ASA stock overvalued right now?
Based on GuruFocus' analysis, Aker BioMarine ASA (OSL:AKBM) is currently considered Significantly Overvalued. The stock's GF Value™ is kr74.55, compared to a current price of kr109.00 — trading 46.2% above its estimated fair value. The current Total Equity is kr1,302 Mil. Aker BioMarine ASA's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Aker BioMarine ASA (OSL:AKBM), the current Total Equity is kr1,302 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aker BioMarine ASA (OSL:AKBM) Overvalued in 2026?
Based on GuruFocus' analysis, Aker BioMarine ASA stock appears to be overvalued.
The current stock price of kr109.00 is trading 46.2% above its estimated GF Value™ of kr74.55.
GuruFocus considers Aker BioMarine ASA to be Significantly Overvalued.
Key valuation signals for OSL:AKBM:
Total Equity: kr1,302 Mil
GF Value™: kr74.55 vs. price of kr109.00 (46.2% above fair value)
No single metric tells the full story. See the OSL:AKBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Products, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.
64GF Score
Get the complete analysis for OSL:AKBM
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:AKBM has been successfully added to your 
